Skip to main content
. 2018 Jun 6;57(20):2975–2980. doi: 10.2169/internalmedicine.0942-18

Table 2.

Reported Cases with Legionnaires’ Disease-associated Fanconi Syndrome.

Case 1 Case 2 Case 3 Case 4 Case 5
Age/Gender 75/M 57/M 65/M 63/M 70/M
Treatment PZFX, GRNX PZFX, LVFX, GRNX AZM LVFX AZM, LVFX
Blood test
Urea nitrogen (mg/dL) 17 41 14 11 13
Creatinine (mg/dL) 0.88 2.23 0.85 0.75 1.05
Uric acid (mg/dL) 2.4 2.7 3.8 1.4 2.1
Sodium (mEq/L) 121 143 128 128 128
Potassium (mEq/L) 3.4 3.5 3.6 3.3 3.9
Chloride (mEq/L) 83 107 91 93 93
Phosphorus (mg/dL) 1.3 2 1.5 1.2 1.9
Creatine phosphokinase (IU/L) 670 2,330 2,999 12,675 8,611
Urinalysis
Protein 2+ 2+ 2+ 2+ 2+
Glucose 3+ 2+ 2+ + 1+
Aminoaciduria + + + + +
%TRP 54 51 47.9 81.1 69
FEUA 18.7 42.8 11.7 18.6 15.5
β2-microglobulin (μg/L) 80,397 110,556 67,900 115,000 83,326
NAG (U/L) 18 19.7 51.2 22.9 58.1
Reference (5) (5) (6) (6) Present case

AZM: azithromycin, FEUA: fractional excretion of uric acid, GRNX: garenoxacin, LVFX: levofloxacin, NAG: N-acetyl-β-D-glucosaminidase, PZFX: pazufloxacin, %TRP: tubular reabsorption of phosphate